{
      "Rank": 352,
      "Acronym": [
            "NEUROSTEM"
      ],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "Allogenic mesenchymal stem cells from bone marrow"
      ],
      "ArmGroupInterventionName": [
            "Procedure: intravitreal injection of MSV"
      ],
      "ArmGroupLabel": [
            "Mesenchymal stem from valladolid (MSV)"
      ],
      "ArmGroupType": [
            "Experimental"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT03173638"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "In this study the investigators propose to perform a Phase II Clinical Trial which seeks to evaluate the safety of cell therapy as a new treatment for patients who suffer from acute non-arteritic anterior ischemic optic neuropathy (NAION). If it is successful, a later study to assess efficacy will be performed.\n\nThis disease has an age-adjusted incidence rate of 10/100.000, and in many cases it results in blindness. Currently, there is no available treatment and second eye involvement occurs in approximately 15-25% of the cases.\n\nAll this background originates a particularly dramatic outcome for the patient. Therefore, it seems justified to evaluate new therapies that maintain or improve the visual function in these patients.\n\nThe Project includes a clinical trial whose purpose is the assessment of the safety of intravitreal administration of allogenic mesenchymal stem cells (MSC) in patients with NAION, a product in clinical research phase (PEI No. 15-007) already approved for other human clinical applications (PEI No. 15-007).\n\nIt can be considered that the therapy with intravitreal injection of MSC is a treatment option in patients with acute NAION, since through the paracrine properties of these cells (secretion of neurotrophic, immunomodulatory and anti-apoptotic factors) it may prevent or reduce the progression of axonal degeneration caused by this disease."
      ],
      "BriefTitle": [
            "Safety Assessment of Intravitreal Mesenchymal Stem Cells for Acute Non Arteritic Anterior Ischemic Optic Neuropathy"
      ],
      "CentralContactEMail": [],
      "CentralContactName": [],
      "CentralContactPhone": [],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [],
      "CollaboratorClass": [
            "OTHER"
      ],
      "CollaboratorName": [
            "University of Valladolid"
      ],
      "CompletionDate": [
            "December 2022"
      ],
      "CompletionDateType": [
            "Anticipated"
      ],
      "Condition": [
            "Non Arteritic Ischemic Optic Neuropathy"
      ],
      "ConditionAncestorId": [
            "D000010335",
            "D000009468",
            "D000009422",
            "D000003389",
            "D000005128",
            "D000014652",
            "D000002318"
      ],
      "ConditionAncestorTerm": [
            "Pathologic Processes",
            "Neuromuscular Diseases",
            "Nervous System Diseases",
            "Cranial Nerve Diseases",
            "Eye Diseases",
            "Vascular Diseases",
            "Cardiovascular Diseases"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC23",
            "All",
            "BC10",
            "BC11",
            "BC14",
            "Rare"
      ],
      "ConditionBrowseBranchName": [
            "Symptoms and General Pathology",
            "All Conditions",
            "Nervous System Diseases",
            "Eye Diseases",
            "Heart and Blood Diseases",
            "Rare Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Ischemic",
            "Optic Neuropathy",
            "Ischemic Optic Neuropathy",
            "Neuropathy",
            "Anterior Ischemic Optic Neuropathy"
      ],
      "ConditionBrowseLeafId": [
            "M9695",
            "M11984",
            "M20106",
            "M12584",
            "M11563",
            "M5757",
            "M7423",
            "M16552",
            "T170",
            "T429"
      ],
      "ConditionBrowseLeafName": [
            "Ischemia",
            "Optic Nerve Diseases",
            "Optic Neuropathy, Ischemic",
            "Peripheral Nervous System Diseases",
            "Neuromuscular Diseases",
            "Cranial Nerve Diseases",
            "Eye Diseases",
            "Vascular Diseases",
            "Acute Graft Versus Host Disease",
            "Anterior Ischemic Optic Neuropathy"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "high",
            "high",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low",
            "high"
      ],
      "ConditionMeshId": [
            "D000010523",
            "D000009901",
            "D000018917",
            "D000007511"
      ],
      "ConditionMeshTerm": [
            "Peripheral Nervous System Diseases",
            "Optic Nerve Diseases",
            "Optic Neuropathy, Ischemic",
            "Ischemia"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "N/A"
      ],
      "DesignInterventionModel": [
            "Single Group Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "None (Open Label)"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [],
      "DetailedDescription": [],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nPatients with acute unilateral NAION (within two weeks after the first symptoms) with at least two of the following:\n\nSudden and unpainful monocular vision loss\nVisual field defects\nDyschromatopsia.\nOcular nerve head edema.\nAfferent relative pupil defect.\nPatients \u2265 50 years old, able to freely give informed consent.\nBest corrected visual acuity (BCVA) \u2264 0,1 in study eye.\nPseudophakia in study eye.\nPreserved pupil sphincter muscle motility\nSigned informed consent form before any study procedure.\nSigned data protection consent form before any study procedure.\n\nExclusion Criteria:\n\nGiant cell arteritis evidence (clinical history, Erythrocyte sedimentation rate (ESR), C-Reactive Protein)\nEvidence of any other etiology that may justify the optic neuropathy (even in the non-study eye)\nHistory of systemic vasculitis, multiple sclerosis, collagenopathies or previous cancer treatments.\nHypersensitivity or allergy to any compound used in the study, including investigational medicinal product (IMP).\nPositive pregnancy test at baseline\nParticipation in any other research study within 2 months\n\nOphthalmic exclusion criteria\n\nHistory of uveitis or active ocular inflammation\nHistory or evidence of glaucoma or high intraocular pressure ( \u2265 24 mmHg in either eye).\nMean opacities or retinal pathologies in the study eye.\nAny previous vitreous or glaucoma surgery in the study eye\nCataract surgery within 3 months in the study eye"
      ],
      "EnrollmentCount": [
            "5"
      ],
      "EnrollmentType": [
            "Actual"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [
            "No"
      ],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [],
      "InterventionAncestorTerm": [],
      "InterventionArmGroupLabel": [
            "Mesenchymal stem from valladolid (MSV)"
      ],
      "InterventionBrowseBranchAbbrev": [],
      "InterventionBrowseBranchName": [],
      "InterventionBrowseLeafAsFound": [],
      "InterventionBrowseLeafId": [],
      "InterventionBrowseLeafName": [],
      "InterventionBrowseLeafRelevance": [],
      "InterventionDescription": [
            "A unique intravitreal injection of MSV in acute fase of NAION"
      ],
      "InterventionMeshId": [],
      "InterventionMeshTerm": [],
      "InterventionName": [
            "intravitreal injection of MSV"
      ],
      "InterventionOtherName": [],
      "InterventionType": [
            "Procedure"
      ],
      "IsFDARegulatedDevice": [
            "No"
      ],
      "IsFDARegulatedDrug": [
            "No"
      ],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "acute non arteritic anterior ischemic optic neuropathy",
            "mesenchymal stem cells",
            "intravitreal injection",
            "safety"
      ],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "April 6, 2021"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "April 5, 2021"
      ],
      "LeadSponsorClass": [
            "OTHER"
      ],
      "LeadSponsorName": [
            "Instituto Universitario de Oftalmobiolog\u00eda Aplicada (Institute of Applied Ophthalmobiology) - IOBA"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Valladolid"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [],
      "LocationCountry": [
            "Spain"
      ],
      "LocationFacility": [
            "IOBA - Applied Ophthalmobiology Institute"
      ],
      "LocationState": [],
      "LocationStatus": [],
      "LocationZip": [
            "47011"
      ],
      "MaximumAge": [
            "80 Years"
      ],
      "MinimumAge": [
            "18 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "Phase II Safety Assessment of Intravitreal Injection of Mesenchymal Stem Cells for Acute Non Arteritic Anterior Ischemic Optic Neuropathy (NAION)"
      ],
      "OrgClass": [
            "OTHER"
      ],
      "OrgFullName": [
            "Instituto Universitario de Oftalmobiolog\u00eda Aplicada (Institute of Applied Ophthalmobiology) - IOBA"
      ],
      "OrgStudyId": [
            "IOBA01-2016"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "IOBA-UVA"
      ],
      "OverallOfficialName": [
            "Jos\u00e9 C Pastor Jimeno, MD, PhD"
      ],
      "OverallOfficialRole": [
            "Principal Investigator"
      ],
      "OverallStatus": [
            "Active, not recruiting"
      ],
      "OversightHasDMC": [
            "Yes"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 2"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "April 2022"
      ],
      "PrimaryCompletionDateType": [
            "Anticipated"
      ],
      "PrimaryOutcomeDescription": [
            "Following the SUN scale, the parameters that will be taken into account in the slit lamp exploration will be: cells and flare in anterior chamber, and vitreous flare"
      ],
      "PrimaryOutcomeMeasure": [
            "Absence of inflammatory reaction - Slit lamp exploration - SUN (Standardization of Uveitis Nomenclature) scale"
      ],
      "PrimaryOutcomeTimeFrame": [
            "Changes compared to baseline in visits V1 (1day), V2 (1week), V3 (1 month), V4 (3 months), V5 (6 months) and V6 (12months) and in any unscheduled visit any patient might need"
      ],
      "ReferenceCitation": [],
      "ReferencePMID": [],
      "ReferenceType": [],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [],
      "ResponsiblePartyInvestigatorFullName": [],
      "ResponsiblePartyInvestigatorTitle": [],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [
            "2016-003029-40"
      ],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [
            "EudraCT Number"
      ],
      "SecondaryOutcomeDescription": [
            "Conjunctival haemorrhages, anterior chamber inflammation, changes in intraocular pressure, infectious endophthalmitis, vitreous inflammation, retinal detachment, choroidal detachment, corneal opacities, lens opacities, neovascularization, macular edema or any other adverse event that may appear"
      ],
      "SecondaryOutcomeMeasure": [
            "Adverse events procedure-related (intravitreal injection)"
      ],
      "SecondaryOutcomeTimeFrame": [
            "Throughout the study after treatment in visits V1 (1day), V2 (1week), V3 (1 month), V4 (3 months), V5 (6 months) and V6 (12months) and in any unscheduled visit any patient might need"
      ],
      "SeeAlsoLinkLabel": [
            "European Union Clinical Trials Register"
      ],
      "SeeAlsoLinkURL": [
            "https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003029-40/ES"
      ],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "March 23, 2018"
      ],
      "StartDateType": [
            "Actual"
      ],
      "StatusVerifiedDate": [
            "April 2021"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "June 2, 2017"
      ],
      "StudyFirstPostDateType": [
            "Actual"
      ],
      "StudyFirstSubmitDate": [
            "May 24, 2017"
      ],
      "StudyFirstSubmitQCDate": [
            "June 1, 2017"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}